Sir, two clarifications. One, our fixed contract revenue that from unit-II and unit-III, so what was the total contribution of the two units?
I understand this is a fixed EBITDA, but what portion of it is currently contributing to our total either in revenue or EBITDA that I wanted to understand?
A few clarities. On CDMO side, can you give the split between innovation related revenues and generic API related revenues? That is one. And secondly, if you could give the revenue from the JV during this quarter?
My question is related to ImmunoACT. When we are expecting it to roll out in India?
Do we have a plan to increase your stake there from 34%?
My question is related to ImmunoACT. When we are expecting it to roll out in India?
Do we have a plan to increase your stake there from 34%?
On ARV side of business, two queries I have, in formulation side the price erosion what we witnessed has stabilized now or we feel that further scope of price erosion is there looking at kind of competition? Second question that in ARV API we saw a good uptick in this quarter. Therefore, again we see that is going to sustain or this will remain volatile quarter-on-quarter?
So, my question was in a context that because the new tender cycle has started for formulations. And we expected that gradually we would see the overall revenue moving up. Then two elements here, so price erosion is one, and I believe that volume has also not been witnessing any uptick. So, am I right that volume is also stable and then price erosion that is impacting or it is volume, we are seeing the improvement but it’s a severe price erosion which has impacted the revenue there?